Debio 0617 is an inhibitor of an undisclosed oncology pathway.
Debiopharm Group and Aurigene Discovery Technologies signed an exclusive worldwide license agreement, excluding the territories of Japan and the rest of Asia, to develop and commercialize Debio 0617, an inhibitor of an undisclosed oncology pathway. Utilizing its fragment-based drug delivery technology platform, Aurigene has generated potent leads against the target. Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development, and sales milestones.
“We are very excited to continue our collaboration with Aurigene. Their business model offers a one-stop solution for structure-guided drug design, lead optimization, and preclinical work. The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and hematological malignancies,” said Rolland-Yves Mauvernay, president and founder of Debiopharm Group.
